

UNAUDITED FINANCIAL RESULTS
FOR THE QUARTER ENDED 31ST MARCH, 2002

Rs in millions

	Quarter Ended		Year Ended		
	31.03.2002	31.03.2001	31.03.2002	31.03.2001 (Audited)	
1	Net Sales	3856.2	2605.6	13868.0	10475.1
2	Other Income	107.4	138.6	440.5	386.1
3	Total Expenditure				
	a) (Increase) / decrease in Stock-in -trade	(444.0)	62.4	(810.9)	(375.8)
	b) Consumption of Materials	2002.4	1280.1	6939.1	5236.6
	c) Staff Cost	178.4	122.9	640.4	499.0
	d) Excise Duty	407.3	139.2	1091.6	808.3
	e) Other Expenditure	910.9	652.6	3196.4	2152.8
4	Interest	5.0	0.9	20.0	8.3
5	Depreciation	71.5	32.5	215.0	156.3
6	Profit (+) / Loss (-) before Tax (1+2-3-4-5)	832.1	453.6	3016.9	2375.7
7	Provision for Taxation	*215.0	110.0	*725.0	585.0
8	Net Profit (+) / Loss (-) (6-7)	617.1	343.6	2291.9	1790.7
9	Paid-up Equity Share Capital	599.7	599.7	599.7	599.7
10	Reserves excluding Revaluation Reserves (as per balance-sheet of previous accounting year)				6540.5
11	Earning per Share ** Not Annualised	**10.29	**5.73	38.21	29.86
12	Aggregate of Non-Promoter Shareholding				
	- Number of Shares	36715294	36505209	36715294	36505209
	- Percentage of Shareholding	61.22	60.87	61.22	60.87

Notes:

- 1 * Provision for tax includes deferred taxation
- 2 The Company is exclusively in the pharmaceutical business segment
- 3 The above results were taken on record at the meeting of the Board of Directors held on 29th April, 2002.

By order of the Board
For **CIPLA LIMITED**

Mumbai
29th April, 2002.

M. K. Hamied
Joint Managing Director